

Supplementary information

Long COVID after breakthrough SARS-CoV-2 infection

In the format provided by the authors and unedited


Supplementary Information

Long COVID after breakthrough SARS-CoV-2 infection


Table of Contents	Page
Supplementary Figures	
Supplementary Figure 1: Standardized mean differences between those with breakthrough SARS-CoV-2 infection and the contemporary control group before and after weighting by organ system.	4
Supplementary Figure 2: Standardized mean differences between those with breakthrough SARS-CoV-2 infection that were non-hospitalized, hospitalized, and admitted to the intensive care unit during the acute phase of the disease and the contemporary control group before and after weighting by organ system.	5
Supplementary Figure 3: Standardized mean differences between those with breakthrough SARS-CoV-2 infection and those with SARS-COV-2 infection without prior vaccination by organ system.	6
Supplementary Figure 4: Standardized mean differences between those with breakthrough SARS-CoV-2 infection and those with SARS-COV-2 infection without prior vaccination that were non-hospitalized, hospitalized, and admitted to the ICU during the acute phase of the disease by organ system.	7
Supplementary Figure 5: Standardized mean differences between those with breakthrough SARS-CoV-2 infection hospitalized during the acute phase of the illness and those hospitalized with seasonal influenza before and after weighting by organ system.	8
Supplementary Figure 6: Risk of post-acute sequelae in people who were hospitalized during the acute phase of breakthrough SARS-CoV-2 infection compared to those hospitalized with seasonal influenza	9
Supplementary Figure 7: Analytic flowchart	10
Supplementary Figure 8: Cohort flowchart	11
Supplementary Figure 9: Rationale and interpretation of the comparative analyses	12
Supplementary Tables	
Supplementary Table 1: Demographic and health characteristics of those with breakthrough SARS-CoV-2 infection, SARS-COV-2 infection without prior vaccination, the contemporary control group, the historical control group, and the vaccinated control group before weighting.	Excel sheet
Supplementary Table 2: Demographic and health characteristics of those with breakthrough SARS-CoV-2 infection and SARS-COV-2 infection without prior vaccination by immunocompromised status before weighting.	Excel sheet
Supplementary Table 3: Demographic and health characteristics of those with breakthrough SARS-CoV-2 infection by vaccine status before weighting.	Excel sheet
Supplementary Table 4: Characteristics and standardized mean differences of those with breakthrough SARS-CoV-2 infection, SARS-COV-2 infection without prior vaccination, and the contemporary control group after weighting.	Excel sheet
Supplementary Table 5: Risk and 6-month burden of death, at least one post-acute sequela, and post-acute sequelae by organ system in breakthrough SARS-CoV-2 infection compared to the contemporary control group.	Excel sheet
Supplementary Table 6: Risk of post-acute sequelae in breakthrough SARS-CoV-2 infection compared to the contemporary control group.	Excel sheet
Supplementary Table 7: Risk and 6-month burden of death, at least one post-acute sequela, and post-acute sequelae by organ system in breakthrough SARS-CoV-2 infection compared to the historical control group.	Excel sheet
Supplementary Table 8: Risk and 6-month burden of death, at least one post-acute sequela, and post-acute sequelae by organ system in breakthrough SARS-CoV-2 infection compared to the vaccinated control group.	Excel sheet

Supplementary Table 9: Risk and burden of death, at least one post-acute sequela, and post-acute sequelae by organ system in breakthrough SARS-CoV-2 infection compared to the contemporary control group in the first 30-90, and 91-180, days of follow-up.	Excel sheet
Supplementary Table 10: Risk and 6-month burden of death, at least one post-acute sequela, and post-acute sequelae by organ system in those with breakthrough SARS-CoV-2 infection by immunocompromised status.	Excel sheet
Supplementary Table 11: Risk and 6-month burden of death, at least one post-acute sequela, and post-acute sequelae by organ system in breakthrough SARS-CoV-2 infection by vaccination type.	Excel sheet
Supplementary Table 12: Demographic and health characteristics of those with breakthrough SARS-CoV-2 infection by care setting of the acute phase before weighting before weighting.	Excel sheet
Supplementary Table 13: Characteristics and standardized mean differences of those with breakthrough SARS-CoV-2 infection by care setting of the acute phase of the disease compared to the contemporary control group after weighting.	Excel sheet
Supplementary Table 14: Risk and 6-month burden of death, at least one post-acute sequela, and post-acute sequelae by organ system in those with breakthrough SARS-CoV-2 infection compared to the contemporary control group by care setting of the acute phase of the disease.	Excel sheet
Supplementary Table 15: Risk of post-acute sequelae in those with breakthrough SARS-CoV-2 infection compared to the contemporary control group by care setting of the acute phase of the disease.	Excel sheet
Supplementary Table 16: Demographic and health characteristics of those with SARS-COV-2 infection without prior vaccination by care setting of the acute phase before weighting.	Excel sheet
Supplementary Table 17: Characteristics and standardized mean differences of those with breakthrough SARS-CoV-2 infection and SARS-COV-2 infection without prior vaccination by care setting of the acute phase of the disease after weighting.	Excel sheet
Supplementary Table 18: Risk and 6-month burden of death, at least one post-acute sequela, and post-acute sequelae by organ system in breakthrough SARS-CoV-2 infection compared to those with SARS-COV-2 infection without prior vaccination.	Excel sheet
Supplementary Table 19: Risk of post-acute sequelae in breakthrough SARS-CoV-2 infection compared to those with SARS-COV-2 infection without prior vaccination.	Excel sheet
Supplementary Table 20: Risk and 6-month burden of death, at least one post-acute sequela, and post-acute sequelae by organ system in those with breakthrough SARS-CoV-2 infection compared to those with SARS-COV-2 infection without prior vaccination by immunocompromised status.	Excel sheet
Supplementary Table 21: Risk and 6-month burden of death, at least one post-acute sequela, and post-acute sequelae by organ system in those with breakthrough SARS-CoV-2 infection compared to those with SARS-COV-2 infection without prior vaccination by care setting of the acute phase of the disease.	Excel sheet
Supplementary Table 22: Demographic and health characteristics of those hospitalized with breakthrough SARS-CoV-2 infection and seasonal influenza before weighting.	Excel sheet
Supplementary Table 23: Characteristics and standardized mean differences of those with breakthrough SARS-CoV-2 infection hospitalized during the acute phase of the disease compared to those hospitalized with seasonal influenza after weighting.	Excel sheet
Supplementary Table 24: Risk and 6-month burden of death, at least one post-acute sequela, and post-acute sequelae by organ system in breakthrough SARS-CoV-2 infection hospitalized during the acute phase compared to those hospitalized with seasonal influenza.	Excel sheet
Supplementary Table 25: Risk of post-acute sequelae in breakthrough SARS-CoV-2 infection hospitalized during the acute phase compared to those hospitalized with seasonal influenza.	Excel sheet


Supplementary Figure 1: Standardized mean differences between those with breakthrough SARS-CoV-2 infection and the contemporary control group before and after weighting by organ system.




Supplementary Figure 2: Standardized mean differences between those with breakthrough SARS-CoV-2 infection that were non-hospitalized, hospitalized, and admitted to the intensive care unit during the acute phase of the disease and the contemporary control group before and after weighting by organ system.




Supplementary Figure 3: Standardized mean differences between those with breakthrough SARS-CoV-2 infection and those with SARS-CoV-2 infection without prior vaccination by organ system.



Supplementary Figure 4: Standardized mean differences between those with breakthrough SARS-CoV-2 infection and those with SARS-CoV-2 infection without prior vaccination that were non-hospitalized, hospitalized, and admitted to the ICU during the acute phase of the disease by organ system.




Supplementary Figure 5: Standardized mean differences between those with breakthrough SARS-CoV-2 infection hospitalized during the acute phase of the illness and those hospitalized with seasonal influenza before and after weighting by organ system.




Supplementary Figure 6: Risk of post-acute sequelae in people who were hospitalized during the acute phase of breakthrough SARS-CoV-2 infection compared to those hospitalized with seasonal influenza.


Incident outcomes were assessed from 30 days after the positive SARS-CoV-2 infection test to end of follow-up. Results are in comparison of those hospitalized with breakthrough SARS-CoV-2 infection (n=3,667) to those hospitalized with seasonal influenza (n=14,337). Adjusted hazard ratios (dots) and 95% confidence intervals (error bars) are presented. Outcomes that occurred in less than 10 participants in a group were excluded.



Supplementary Figure 7: Analytic flowchart.



Supplementary Figure 8: Cohort flowchart.



Supplementary Figure 9: Rationale and interpretation of the comparative analyses

